title: Genetics of alcoholism: role of the endogenous opioid system.
abstract: At the present time alcoholism is recognized as a metabolic disease exhibiting the clinical features of craving for alcohol, loss of control over drinking, tolerance and physical dependence on alcohol, while both epidemiological and experimental studies have demonstrated that genetic factors may be important in determining whether an individual has a high or low vulnerability to develop alcoholism. Evidence also indicates that alcoholism is not characterized by a single gene single allele inheritance. Instead it seems that multiple genes and environmental factors interact to increase or decrease an individual's vulnerability to become an alcoholic. Current research is aimed at investigating whether certain behavioral, physiological and biochemical markers are highly associated with the incidence of alcoholism. Among the biochemical markers currently under investigation is the endogenous opioid system and its implication in mediating the reinforcing effects of ethanol. It is the objective of this manuscript to review current research on: (a) the interactions of ethanol with the endogenous opioid system at the molecular level; (b) the existence of genetically determined differences in the response of the endogenous opioid system to ethanol between subjects at high and low risk for excessive ethanol consumption, as well as between lines of animals showing preference or aversion for ethanol solutions; (c) the decrease of alcohol consumption following pretreatment with opioid antagonists; and (d) the possible use of specific opioid receptor antagonists together with behavioral therapy to modify drinking behavior, to control craving and to prevent relapse.
authors.affiliation: Douglas Hospital Research Centre, Montreal, Quebec, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Gianoulakis
authors.forename: J P
authors.initials: JP
authors.lastname: de Waele
mesh_terms: D000428:Alcohol Drinking; D000437:Alcoholism / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000517:prevention & control; D000818:Animals; D015415:Biomarkers; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004327:Drinking Behavior / Q000187:drug effects; D004723:Endorphins / Q000037:antagonists & inhibitors / Q000502:physiology*; D000431:Ethanol / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D009292:Narcotic Antagonists / Q000494:pharmacology; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011957:Receptors, Opioid / Q000187:drug effects / Q000502:physiology*
chemical_list: D015415:Biomarkers; D004723:Endorphins; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D000431:Ethanol